ROS1 and non-small cell lung carcinoma: Despite the fact that ceritinib may be a promising treatment option for ROS1-positive NSCLC based on this study, several crizotinib-resistant ROS1 mutations such as G2032R, D2033N, L1951R, and S1986Y/F cannot be overcome by ceritinib [67,68].